NeOnc Technologies Appoints David Choi as Chief Accounting Officer
Rhea-AI Summary
NeOnc Technologies (Nasdaq: NTHI) appointed David Choi as Chief Accounting Officer effective March 13, 2026. Mr. Choi will oversee accounting, financial reporting, internal controls, and corporate governance as NeOnc advances its Phase 2 clinical programs for central nervous system cancers and expands global operations.
Mr. Choi has more than a decade of experience, previously served as Director at Blythe Global Advisors, held roles at Grant Thornton and Ernst & Young, and is a Certified Public Accountant with graduate and undergraduate degrees from University of California, Irvine.
Positive
- Appointment dated March 13, 2026 of David Choi as Chief Accounting Officer
- Experience of more than a decade in accounting and public company reporting
- Professional credentials include CPA and advanced accountancy degree
Negative
- None.
Market Reality Check
Peers on Argus
Before this leadership news, NTHI was down 4.36% while key biotech peers like ELTX (-6.84%) and CCCC (-6.14%) were also weaker, but scanner data shows only one peer in momentum and no broad, same-direction sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Analyst update | Positive | -4.4% | Stonegate updated coverage on CNS oncology pipeline and financing position. |
| Mar 04 | Clinical results | Positive | +4.9% | Phase 1 NEO212 dose-escalation results and Phase 2 planning disclosed. |
| Feb 27 | Investor call notice | Neutral | +1.3% | Announcement of upcoming investor call on NEO212 Phase 1 results. |
| Jan 30 | PIPE financing | Negative | +5.9% | PIPE with shares and five-year warrants for up to $16M gross proceeds. |
| Jan 09 | Coverage initiation | Positive | -3.5% | Stonegate initiated coverage highlighting NEO100 and upcoming catalysts. |
Recent history shows mixed alignment: positive clinical and financing updates sometimes coincided with gains, but analyst coverage and initiation pieces saw negative next-day moves, indicating frequent divergence between news tone and price reaction.
Over the past few months, NeOnc has advanced its CNS oncology programs and balance sheet. A Jan 30 PIPE financing with warrants lifted shares by 5.94%, while a Mar 4 Phase 1 NEO212 readout saw a 4.9% gain. In contrast, Stonegate’s coverage initiation on Jan 9 and updated report on Mar 12 were followed by declines of 3.5% and 4.36%. Against this backdrop, today’s management appointment fits into an ongoing build-out of capabilities around growing clinical and public-company demands.
Market Pulse Summary
This announcement highlights NeOnc’s effort to deepen its finance and governance bench as it advances multi‑Phase 2 CNS oncology programs. Appointing a Chief Accounting Officer with SEC reporting and SOX compliance experience aligns with the demands of recent financings and clinical progress. In context of prior PIPE transactions and ongoing trial work, investors may watch how strengthened controls support future filings, capital raises, and execution of NEO100 and NEO212 development plans.
Key Terms
central nervous system medical
cns cancers medical
sec reporting regulatory
sox compliance regulatory
equity instruments financial
debt financing financial
business combinations financial
AI-generated analysis. Not financial advice.
CALABASAS, Calif., March 13, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system (CNS) cancers, has appointed David Choi as Chief Accounting Officer. In this role, Mr. Choi is responsible for overseeing the Company’s accounting, financial reporting, internal controls, and corporate governance functions as NeOnc advances its clinical-stage biotechnology platform and expands its global operations.
“David’s extensive expertise in technical accounting and financial reporting for public companies comes at a pivotal time for NeOnc,” said Amir Heshmatpour, Chairman and CEO of NeOnc. “As we accelerate our clinical trials and prepare for the next stages of corporate growth, maintaining rigorous financial controls and governance is essential. David’s proven track record at top-tier advisory firms makes him an invaluable addition to our leadership team as we strive to deliver novel therapies to patients with CNS cancers.”
“I am honored to join NeOnc at such an exciting inflection point in its development,” said Mr. Choi. “NeOnc is doing vital work in the fight against aggressive brain cancers, and I look forward to applying my experience in financial infrastructure and compliance to support the Company’s strategic objectives. My focus will be on ensuring we have the robust financial foundation necessary to support our clinical advancements and drive long-term value for our shareholders.”
Mr. Choi has more than a decade of experience in accounting, financial reporting, and internal controls for both public and private companies. Prior to joining NeOnc, Mr. Choi was a Director at Blythe Global Advisors, where he advised companies across multiple industries on technical accounting matters, SEC reporting, and SOX compliance. He led engagements involving financial reporting transformation, internal control design and implementation, and accounting for complex transactions including equity instruments, debt financing, and business combinations.
Earlier in his career, Mr. Choi held positions at Grant Thornton and Ernst & Young, where he provided assurance and advisory services to public and private companies. His experience includes financial statement audits, technical accounting advisory, and SOX readiness and compliance for internal controls over financial reporting.
Mr. Choi is a Certified Public Accountant (CPA). He holds a Master of Professional Accountancy and a Bachelor of Arts in Business Economics with a minor in Accounting from the University of California, Irvine.
ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.
For more about NeOnc and its pioneering technology, visit https://neonc.com
Important Cautions Regarding Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward-looking information.
Please refer to the “Risk Factors” section of our Quarterly Report on Form 10-Q for the three months ended March 31, 2025 as filed with the Securities and Exchange Commission, along with other cautionary language in that report and risk factors and other cautionary language in our subsequent filings with the Securities and Exchange Commission, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward-looking statements herein, including but not limited to the fact that results of preclinical studies and early clinical trials may not be predictive of results of future clinical trials, announced or published data from our clinical trials may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data and our product candidates are in preclinical and clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable.
We assume no obligation to revise or update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.
“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Company Contact:
Investor Contact:
James Carbonara
Hayden IR
(646)-755-7412
FAQ
Who is David Choi and what role did NeOnc (NTHI) appoint him to on March 13, 2026?
What responsibilities will David Choi have as Chief Accounting Officer of NeOnc (NTHI)?
What relevant experience does NeOnc (NTHI) cite for David Choi’s appointment?
Is David Choi a licensed accountant and what are his academic credentials mentioned by NeOnc (NTHI)?
How might David Choi’s background affect NeOnc (NTHI) governance and SOX readiness?
When did NeOnc (NTHI) announce David Choi’s appointment and where is the company headquartered?
